Select language:  
1800 620 420
Close menu

Blood Cancer Genomics Trial (MoST-LLy)

A new clinical trial research program offering Australians with blood cancer genomic screening and potential access to precision medicines.

The Blood Cancer Genomics Trial (MoST-LLy) research program will leverage the science powering the Molecular Screening and Therapeutics Program (MoST) – a clinical trial which until now has focused only on solid tumours.  

The trial will initially focus on high grade lymphomas and acute leukaemias. These types of blood cancer are aggressive, with few treatment options available for people who don’t respond to initial treatment or when they relapse.  

Using the science of genomic testing and precision medicine, this trial aims to identify the best treatment for each individual patient, with the potential for improved survival, fewer side effects and greater quality of life. 

Genomic testing informs precision medicine – that is, it helps identify the best treatment for each individual patient, with the potential for improved survival, fewer side effects and greater quality of life. 

The Blood Cancer Genomics Trial (MoST-LLy) is the first genomics screening program of its kind for blood cancers in Australia, with potential to improve outcomes for Australians with advanced, high-risk blood cancers.

The importance of improving access to genomic screening and clinical trials cannot be overstated. If we are to have any hope of reducing blood cancer mortality in this country, we must shift our focus away from treating blood cancer subtypes with a ‘one size fits all’ approach and towards targeted therapies

Chris Tanti, CEO, Leukaemia Foundation.

Wondering how genomic testing worksWatch our simple explainer video here.  

  • Genomic screening has revolutionised understanding of blood cancers and paved the way to a new generation of new precision medicines, where treatments are targeted based on an individual’s blood cancer genomic profile. Until recently it has been almost impossible to target treatments to a person’s unique genetic makeup, resulting in a ‘one size fits all’ approach to treatment.
  • Genomic profiling is required for accurate subtype diagnosis and the subsequent treatment of blood cancer patients. Through genomic profiling, clinicians can more precisely match patients to targeted therapies. These efforts are critical to the expansion of precision medicine and the realisation of curative therapies.
  • The National Strategic Action Plan for Blood Cancer includes recommendations around genetic screening, including developing guidelines for diagnostics and reviewing Australia’s capacity to meet these guidelines, as well as recommendations to enable access to novel and specialised therapies, including actions to improve equitable access to these therapies and making precision medicine the standard of care.

The Leukaemia Foundation and Tour de Cure are proud to be the joint driving force behind the Blood Cancer Genomics Trial: a powerful partnership between researchers and medical centres across the country.  

The pilot $1.8 million program allows the screening of 240 patients initially and is proudly co-funded by the Leukaemia Foundation and Tour de Cure. Screening is now open to patients at Royal Brisbane and Women’s Hospital, with South Australia expected to open to recruitment later this year and SA Pathology providing molecular screening for the program across both states. 

Interested patients should discuss this trial with their haematologist.

Tour de Cure

This is a collaboration between the Royal Brisbane and Women’s Hospital, Royal Adelaide Hospital, QIMR Berghofer Medical Research Institute, SA Pathology, Garvan Institute of Medical Research, Omico (the Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre at the University of Sydney.  

Hear from Professor Steven Lane about how the Blood Cancer Genomics Trial (MoST-LLy) works.